0001209191-19-045818.txt : 20190813
0001209191-19-045818.hdr.sgml : 20190813
20190813195241
ACCESSION NUMBER: 0001209191-19-045818
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190813
FILED AS OF DATE: 20190813
DATE AS OF CHANGE: 20190813
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Daniel Lee
CENTRAL INDEX KEY: 0001713712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 191022409
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC
STREET 2: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 500 TOTTEN POND ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-08-13
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001713712
Flynn Daniel Lee
C/O DECIPHERA PHARMACEUTICALS, INC.
500 TOTTEN POND ROAD
WALTHAM
MA
02451
0
1
0
0
Chief Scientific Officer
Common Stock
2019-08-13
4
M
0
123107
1.89
A
147607
D
Common Stock
2019-08-13
4
S
0
93395
40.2628
D
54212
D
Common Stock
2019-08-13
4
S
0
29712
41.3271
D
24500
D
Common Stock
2019-08-13
4
S
0
25000
42.90
D
66779
I
By Daniel L. Flynn Irrevocable Trust
Common Stock
55270
I
By Biochenomix, LLC
Stock Option (Right to Buy)
1.89
2019-08-13
4
M
0
123107
0.00
D
2025-12-17
Common Stock
123107
349571
D
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.995, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.00 to $41.805, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015.
/s/ Thomas P. Kelly, Attorney-in-Fact
2019-08-13